Intensive short-term treatment with rituximab, cyclophosphamide and methylprednisolone pulses induces remission in severe cases of SLE with nephritis and avoids further immunosuppressive maintenance therapy

Nephrology Dialysis Transplantation

Volumn 26, Issue 12, 2011, Pages 3987-3992

  Roccatello, Dario ^a   Sciascia, Savino ^a   Rossi, Daniela ^a   Alpa, Mirella ^a   Naretto, Carla ^a   Baldovino, Simone ^a   Menegatti, Elisa ^a   La Grotta, Rita ^a   Modena, Vittorio ^a  

^a Centro di Ricerche di Immunopatologia e Documentazione Su Malattie Rare (CMID)   (Italy)

Author keywords

lupus nephritis; rituximab; systemic lupus erythematosus

Indexed keywords

ACETYLSALICYLIC ACID; CREATININE; CYCLOPHOSPHAMIDE; DOUBLE STRANDED DNA ANTIBODY; HYDROXYCHLOROQUINE; LOW MOLECULAR WEIGHT HEPARIN; METHYLPREDNISOLONE; PREDNISONE; RITUXIMAB;

ADULT; ANTIBODY BLOOD LEVEL; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BRADYCARDIA; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; MAINTENANCE THERAPY; MALE; MYALGIA; PERICARDITIS; POLYARTHRITIS; PRIORITY JOURNAL; SHORT COURSE THERAPY; TREATMENT DURATION; TREATMENT RESPONSE; URINARY TRACT INFECTION;

ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CYCLOPHOSPHAMIDE; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MALE; METHYLPREDNISOLONE; MIDDLE AGED; PROSPECTIVE STUDIES; REMISSION INDUCTION; TIME FACTORS;

EID: 80051863465     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr109     Document Type: Article

References (37)

1. Looney RJ, Anolik JH, Campbell D et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004; 50: 2580-2589 (Pubitemid 39062719)
2. Leandro MJ, Cambridge G, Edwards JC et al. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology 2005; 44: 1542-1545 (Pubitemid 41742472)
3. Marks SD, Patey S, Brogan PA et al. B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus. Arthritis Rheum 2005; 52: 3168-3174 (Pubitemid 41447099)
4. Smith KGC, Jones RB, Burns SM et al. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment. Arthritis Rheum 2006; 54: 2970-2982 (Pubitemid 44497778)
5. Merrill JT, Neuwelt CM, Wallace DJ et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010; 62: 222-233
6. Furie R, Looney RJ, Rovin B et al. Efficacy and safety of rituximab in subjects with active proliferative lupus nephritis: results from the randomized, double-blind phase III LUNAR study. [abstract]. Arthritis Rheum 2009; 60 (Suppl 10): 1149
7. Ramos-Casals M, D́az-Lagares C, Khamashta MA. Rituximab and lupus: good in real life, bad in controlled trials. Comment on the article by Lu et al. Arthritis Rheum 2009; 61: 1281-1282
8. Levey AS, Bosch JP, Lewis JB et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470 (Pubitemid 29135798)
9. Cambridge G, Leandro MJ, Teodorescu M et al. B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles. Arthritis Rheum 2006; 54: 3612-3622 (Pubitemid 44737173)
10. Vallerskog T, Gunnarsson I, WidheMet al. Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clin Immunol 2007; 122: 62-74 (Pubitemid 46026695)
11. Anolik JH, Barnard J, Cappione A et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 2004; 50: 3580-3590 (Pubitemid 39488683)
12. Sfikakis PP, Boletis JN, Lionaki S et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum 2005; 52: 501-513 (Pubitemid 40216314)
13. Gunnarsson I, Sundelin B, Jonsdottir T et al. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide resistant proliferative lupus nephritis. Arthritis Rheum 2007; 56: 1263-1272 (Pubitemid 46608651)
14. Gillis JZ, Dall'era M, Gross A et al. Six refractory lupus patients treated with rituximab: a case series. Arthritis Rheum 2007; 57: 538-542 (Pubitemid 46682546)
15. Levesque MC, St Clair EW. B cell-directed therapies for autoimmune disease and correlates of disease response and relapse. J Allergy Clin Immunol 2008; 121: 13-21
16. Silverman GJ, Carson DA. Roles of B cells in rheumatoid arthritis. Arthritis Res Ther 2003; 5 (Suppl 4): S1-S6 (Pubitemid 38239909)
17. Lund FE, Garvy BA, Randall TD et al. Regulatory roles for cytokineproducing B cells in infection and autoimmune disease. Curr Dir Autoimmun 2005; 8: 25-54
18. Mebius RE, Van Tuijl S, Weissman IL et al. Transfer of primitive stem/progenitor bone marrow cells from LT alpha-/-donors to wild-type hosts: implications for the generation of architectural events in lymphoid B cell domains. J Immunol 1998; 161: 3836-3843 (Pubitemid 28468956)
19. Leandro MJ, Cambridge G, Ehrenstein MR et al. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54: 613-620 (Pubitemid 43228639)
20. Todd DJ, Helfgott SM. Serum sickness following treatment with rituximab. J Rheumatol 2007; 34: 430-433
21. Andersohn F, Konzen C, Garbe E. Systematic review: agranulocytosis induced by nonchemotherapy drugs. Ann Intern Med 2007; 146: 657-665 (Pubitemid 351650522)
22. Nitta E, Izutsu K, Sato T et al. A high incidence of late-onset neutropenia following rituximab-containing chemotherapy as a primary treatment of CD20-positive B-cell lymphoma: a single-institution study. Ann Oncol 2007; 18: 364-369 (Pubitemid 46323107)
23. Anonymous. Rituxan warning. FDA Consumer 2007; 41: 3
24. Arnold DM, Dentali F, Crowther MA et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 2007; 146: 25-33 (Pubitemid 351650318)
25. Genovese M, Emery P, Ruderman E et al. Immunoglobulin levels and infection rates in patients with rheumatoid arthritis (RA) treated with repeated courses of rituximab. Arthritis Rheum 2007; 56: S149
26. Gea-Banacloche JC. Rituximab-associated infections. Semin Hematol 2010; 47: 187-198
27. Roccatello D, Baldovino S, Rossi D et al. Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis. Nephrol Dial Transplant 2004; 19: 3054-3061 (Pubitemid 40057628)
28. Roccatello D, Baldovino S, Rossi D et al. Rituximab as a therapeutic tool in severe mixed cryoglobulinemia. Clin Rev Allergy Immunol 2008; 34: 111-117
29. Roccatello D, Baldovino S, Alpa M et al. Effects of anti-CD20 monoclonal antibody as a rescue treatment for ANCA-associated idiopathic systemic vasculitis with or without overt renal involvement. Clin Exp Rheumatol 2008; 26 (3 Suppl 49): S67-S71
30. Cavallo R, Roccatello D, Menegatti E et al. Rituximab in cryoglobulinemic peripheral neuropathy. J Neurol 2009; 256: 1076-1082
31. Silverman GJ. Therapeutic B cell depletion and regeneration in rheumatoid arthritis: emerging patterns and paradigms. Arthritis Rheum 2006; 54: 2356-2367 (Pubitemid 44204995)
32. Melander C, Sallée M, Trolliet P et al. Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome. Clin J Am Soc Nephrol 2009; 4: 579-587
33. Gong Q, Ou Q, Ye S et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol 2005; 174: 817-826 (Pubitemid 40094277)
34. Lu TY, Ng KP, Cambridge G et al. Retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at university college London hospital: the first fifty patients. Arthritis Rheum 2009; 61: 482-487
35. Pepper R, Griffith M, Kirwan C et al. Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids. Nephrol Dial Transplant 2009; 24: 3717-3723
36. Jonsdottir T, Gunnarsson I, Risselada A et al. Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response. Ann Rheum Dis 2008; 67: 330-334 (Pubitemid 351281266)
37. Lightstone L. Lupus nephritis: where are we now? Curr Opin Rheumatol 2010; 22: 252-256